Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01656603
Other study ID # 6637-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 2012
Est. completion date December 2025

Study information

Verified date March 2024
Source New York Blood Center
Contact Dorothy Sung
Phone 718-706-5202
Email dsung@nybc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.


Description:

The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP hematopoietic progenitor cell-cord blood (HPC-CORD BLOOD) products in a multi-institution setting. Therefore, the study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of the unlicensed, investigational NCBP CBU. Definitions of Infusion-related adverse reactions: Mild - Moderate: reactions during or after the infusion of the cord blood (CB) product that require some medical intervention but do not affect the overall patient status or outcome. Severe: serious, life-threatening or fatal infusion reactions, requiring major medical intervention. These include: anaphylactic shock, acute cardiac, pulmonary or renal failure, seizures, patient transfer to the Intensive Care Unit, or death within 48 hours of the CB infusion. Adverse Reactions will also be classified by grade, according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE).


Other known NCT identifiers
  • NCT01861093

Recruitment information / eligibility

Status Recruiting
Enrollment 9999
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Diagnosis: Patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. 2. Patients: Patients of any age and either gender 3. Cord blood product manufactured by the NCBP (at least one, if the graft contains more than one units) Exclusion Criteria: 1. Patients who are receiving licensed cord blood products (only) 2. Patients who are receiving unlicensed cord blood products from other banks (only) 3. Patients who are transplanted at non-US transplant centers 4. Patients who are receiving cord blood products that will be "manipulated" post-thaw (e.g., ex vivo expansion, incubation in vitro, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
unlicensed CBU
infusion of unlicensed cord blood units

Locations

Country Name City State
United States Akron Children's Hospital Akron Ohio
United States Children's Healthcare of Atlanta Atlanta Georgia
United States Northside Hosptal Atlanta Georgia
United States The Children's Hospital of Colorado Aurora Colorado
United States University of Colorado Hospital Aurora Colorado
United States National Institutes of Health Bethesda Maryland
United States Children's of Alabama Birmingham Alabama
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Instistute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Medical University of South Carolina Charleston South Carolina
United States University of Virginia Charlottesville Virginia
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Northwestern Memorial Hospital Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Cleveland Clinic Foundation Cleveland Ohio
United States Seidman Cancer Center Cleveland Ohio
United States Arthur G. James Cancer Hospital Columbus Ohio
United States Nationwide Children's Hospital Columbus Ohio
United States Children's Medical Center of Dallas Dallas Texas
United States Presbyterian / St. Luke's Medical Center Denver Colorado
United States Children's Hospital of Michigan Detroit Michigan
United States Henry Ford Health System Detroit Michigan
United States City of Hope Duarte California
United States Cook Children's Medical Center Fort Worth Texas
United States Helen DeVos Children's Hospital Grand Rapids Michigan
United States Penn State Health / Penn State Milton S. Hershey Medical Center Hershey Pennsylvania
United States Texas Children's Cancer Center Houston Texas
United States Indiana University Indianapolis Indiana
United States University of Mississippi Medical Center Jackson Mississippi
United States Nemour's Children's Clinic and Hospital Jacksonville Florida
United States UCSD Moores Cancer Center La Jolla California
United States Northwell Health - North Shore University Hospital Lake Success New York
United States Cedars Sinai Medical Center Los Angeles California
United States UCLA Healthcare Los Angeles California
United States James Graham Brown Cancer Center Louisville Kentucky
United States University of Wisconsin Hospital and Clinics Madison Wisconsin
United States Loyola University Medical Center Maywood Illinois
United States St Jude Children's Research Center Memphis Tennessee
United States University of Miami Health System Sylvester Comprehensive Cancer Center Miami Florida
United States University of Miami/Jackson Memorial Hospital Miami Florida
United States Children's Hospital of Wisconsin Milwaukee Wisconsin
United States West Virginia University Hospitals Inc Morgantown West Virginia
United States Cohen Children's Medical Center of NY New Hyde Park New York
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Mount Sinai Hospital New York New York
United States New York Presbyterian Hospital WCMC New York New York
United States Stephenson Oklahoma Cancer Center Oklahoma City Oklahoma
United States The Nebraska Medical Center Omaha Nebraska
United States Florida Hospital, Florida Center for Cellular Therapy Orlando Florida
United States Abramson Cancer Center of the University of Pennsylvania Medical Center Philadelphia Pennsylvania
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Mayo Clinic Arizona Phoenix Arizona
United States Phoenix Children's Hospital Phoenix Arizona
United States Children's Hopsital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Doernbecher Children's Hospital / Oregon Health & Science University Portland Oregon
United States Virginia Commonwealth University Massey Cancer Center Richmond Virginia
United States Mayo Clinic Rochester Rochester Minnesota
United States University of Rochester Medical Center Rochester New York
United States Barnes-Jewish Hospital at University of Washington / Sireman Cancer Center Saint Louis Missouri
United States St. Louis University Hospital Saint Louis Missouri
United States All Children's Hospital, John Hopkins Medicine Saint Petersburg Florida
United States Methodist Hospital / Texas Transplant Institute San Antonio Texas
United States Rady Children's Hospital San Diego California
United States Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance Seattle Washington
United States Stanford Health Care Stanford California
United States University of Arizona Medical Center Tucson Arizona
United States Southwestern Regional Medical Center Tulsa Oklahoma
United States Children's National Medical Center Washington District of Columbia
United States Alfred I. DuPont Hospital for Children Wilmington Delaware
United States Midwestern Regional Medical Center Zion Illinois

Sponsors (1)

Lead Sponsor Collaborator
New York Blood Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of infusion-related reactions The primary aim of this study is to examine the safety of administration of the unlicensed investigational cord blood products in a multi-institution setting. The study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of the unlicensed, investigational NCBP cord blood units. within 48 hours of infusion
Secondary engraftment This outcome will evaluate engraftment of unlicensed cord blood units six months after transplant